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Abstract
Purposes The purpose of this study was to retrospectively
study embryonal tumors with multilayered rosettes (ETMR),
a rare new entity that gathers ETAN-TR (embryonal tumor with
abundant neuropil and true rosettes), ependymoblastomas, and
medulloepitheliomas, in order to improve their descriptions and
try to better define therapeutic modalities.
Methods Patients with ETMR, ETAN-TR, ependymoblastoma,
and medulloepithelioma treated in SFCE centres (Société
Française de lutte contre les Cancers et les leucémies de l'Enfant
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et de l'adolescent) since 2000 were collected. Data were retrieved
from clinical charts.
Results Thirty-eight patients were included in the analysis.
Seventeen had an ETAN-TR, 13 had a medulloepithelioma,
and 8 had an ETMR. No ependymoblastoma was included.
The median age at diagnosis was 31 months (range, 2.8–
141 months). The predominant tumor location was
supratentorial (66 %); 18.4 % patients had metastatic lesion.
LIN28A expression was positive in 11/11 patients. Amplifi-
cation of the locus 19q13.42 was positive in 10/12 patients.
Thirty patients were treated according to the primitive
neuroectodermal tumors of high risk (PNET-HR) protocol. The
median time of follow-upwas 0.9 years (range 0.1 to 15.3 years).
The 1-year event-free survival (EFS) and overall survival (OS)
were, respectively, 36 % CI 95 % (23–55) and 45 % CI 95 %
(31–64). On multivariate analysis, complete surgical resection,
radiotherapy, and high-dose chemotherapy were associated with
a better overall survival with a relative risk of, respectively, 7.9
CI 95 % (2.6–23.5) p < 0.0002, 41.8 CI 95 % (9.4–186)
p < 0.0001, and 3.5 CI 95 % (1.3–9.5) p = 0.012.
Conclusion Prognosis of ETMR remains dismal despite mul-
timodal therapy. LIN28A immunostaining and 19q13.42 am-
plification should be systematically done to secure the diag-
nosis. Complete surgical resection, radiotherapy, and high-
dose chemotherapy are associated with better outcome.
Keywords Brain tumors .Children .Radiotherapy .Surgery .
Chemotherapy . ETMR
Introduction
Embryonal tumors with neuropil and true rosettes abundant
(ETAN-TR), ependymoblastomas, and medulloepitheliomas
are three distinct pathologies which actually represent
different manifestations of the same histological and biologi-
cal entity [1, 2]. The term embryonal tumors with multilayered
rosettes (ETMR) was proposed in 2010 as a unifying entity by
Paulus and Kleihues [3] as the histological central element
found in these tumors was the presence of multilayered ro-
settes. Moreover, ETMR seem to have a specific molecular
signature with a positivity of LIN28A on immuno-
histochemistry and amplification of the locus 19q13.42 in
FISH analysis [4, 5]. ETMR belongs to the group of the prim-
itive neuroectodermal tumors of the central nervous system
(PNET) according to the World Health Organization (WHO)
classification [6].
ETMR are quite rare entities; their prevalence is not accu-
rately estimated. They are likely under-diagnosed with only a
few cases reported in the literature since 2000 [2, 3, 7, 8]. They
occur mostly in children aged less than 2 years old. In the
literature, the localization of the majority of the primitive tu-
mor is supratentorial with signs of increased intracranial pres-
sure. Treatment of ETMR usually starts with maximal surgical
resection. The role of adjuvant treatment with either chemo-
therapy and/or radiotherapy has not yet been well established
for this disease.
To improve our knowledge about ETMR, we collected
cases treated in SFCE centers (Société Française des Cancers
et leucémies de l’Enfant et de l’adolescent) from January 2000
to May 2014 in order to retrospectively study clinical, radio-
logical, biological, and prognostic descriptions to improve
their descriptions and try to better define therapeutic
modalities.
Patients and methods
Study design, patients, data collection
Patients aged less than 18 years with newly diagnosed ETMR
who were treated in France between January 2000 and 1
May 2014 were identified retrospectively by consulting local
oncologists’ and pathologists’ databases in SFCE centers
using the following diagnosis: ETMR, ETAN-TR,
ependymoblastoma, and medulloepithelioma. A standardized
data sheet was sent to pediatric oncologists who were mem-
bers of the SFCE to collect clinical data. The questionnaire
included information about sex, age at time of presentation,
duration of the symptoms at time of presentation, location of
tumor, extent of resection (complete resection, partial resec-
tion, biopsy), pathological biological andmolecular diagnosis,
adjuvant therapies, and follow-up. At diagnosis, stage of dis-
ease was evaluated by initial cranial and spinal MRI and CSF
cytology. The extent of initial resection was assessed by MRI
or computed tomography performed within 72h after surgery.
Metastatic disease was assessed using the Chang staging sys-
tem. Tumors were subjected to a central histopathological
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review by members of the national pediatric brain tumors
board (GENOP). When it was feasible, immuno-
histochemistry analysis applying a LIN28A polyclonal anti-
body and array-based comparative genomic hybridization
(CGHarray) was performed. The data were coded to ensure
confidentiality. This study has been approved by the National
Ethical Committee (CCTIRS).
Statistical analysis:
Relapses and deaths were considered as events. Event-free sur-
vival (EFS), overall survival (OS), and univariate analysis were
estimated by the Kaplan-Meier method, and differences be-
tween groups were assessed by the log-rank test. Survival esti-
mates referred to 1 and 3 years from diagnosis and the related
95 % confidence intervals (95 % CI) were calculated. Cox
model was used to calculate the multivariate analysis by a step-
wise selection. Descriptive statistics were reported as absolute
frequencies and percentages for qualitative data, while median
and range were used for continuous variables. When
performing univariate analysis, those variables were used: age
≤4 years or >4 years, age <4 years or 4 to 5 years or 5 to 8 years
or 8 to 11 years, histological diagnosis (ETMR, ETAN-TR,
medulloepithelioma, ependymoblastoma), surgery, chemother-
apy, radiotherapy, high-dose chemotherapy, and primitive
neuroectodermal tumors of high risk (PNET-HR) (yes or no).
Positive variables identified with univariate analysis were used
in the multivaried analysis. All statistical tests were two sided
and a Bp^ value <0.05 was considered significant. Statistical
analysis was performed using R version 3.0.2.
Results:
Patients’ characteristics
Forty-two patients with an ETMRwere identified in the SFCE
centers, but 4 patients were excluded because data could not
be retrieved or the diagnosis was uncertain. Thirty-eight pa-
tients were therefore analyzed. The median age at diagnosis
was 31.1 months (range 2.8–141 months) and the sex ratio
was 0.4 (male/female). Main clinical signs were a sided weak-
ness (34 %) and increased intracranial pressure (53 %). Con-
fusion, seizures, and cerebellar syndrome occurred in 26, 21,
and 21 % of children, respectively. Torticollis occurred in 8 %
of cases and visual impairment was found in 11 % of patients.
The predominant tumor location was supratentorial (66 %).
Tumors were infratentorial in the others (26 %). One patient
had a medullar lesion. Eighteen percent of patients had meta-
static disease at initial presentation. In all cases, the metastasis
was evidenced by MRI while metastatic cells were never
found in the cerebrospinal fluid at the time of diagnosis.
Histopathological characteristics
A histopathological review was performed in 100 % of the 38
patients. Noteworthy, 6 children had an uncorrect diagnosis (1
ependymoma, 5 PNET). Seventeen patients had ETAN-TR,
13 had medulloepithelioma, 8 had ETMR, and 0 had
ependymoblastoma (Table 1). LIN28A expression was
searched for 11 patients and was positive in 100 % of the
cases. The amplification of the locus 19q13.42, searched for
in 12 children, was present in 83% of the patients. The gain of
the chromosome 2 and other chromosome gains were
searched for in 11 patients and were positive, respectively, in
27 and 54 % of the cases. Data are summarized in Table 2.
Treatment strategy and outcome
All children but 8 were treated according to the PNET-HR
protocol. The strategy relies on the combination of surgery,
conventional chemotherapy (2 courses of etoposide-
carboplatin), followed by sequential high-dose chemother-
apy (melphalan/cisplatinum/melphalan/cisplatinum/thiote-
pa) each course being followed by peripheral blood stem
cell transplantation and reduced dose radiation therapy [9].
Details of all the 38 patients are provided in Table 3.
All children received adjuvant chemotherapy, after a com-
plete resection for 12 patients, or a partial resection/biopsy for
18 patients. Out of the 30 patients who received etoposide/
carboplatinum, 4 experienced disease progression (1 who had
a complete resection and 3 who had a partial resection). In
patients who underwent complete resection, 6 children re-
ceived the complete PNET-HR protocol and 3 are alive with
a follow-up of, respectively, 12, 8.6, and 3.6 years. Out of the
patients who had a post-surgery residual disease (18 patients),
only two completed the whole protocol PNET-HR. The re-
maining patients presented tumor progression and all patients
but 2 died.
Among the patients who were not treated according the the
PNET-HR protocol, one child with a localized ETMR
underwent a complete removal of the tumor after 2 surgeries.
CSF became positive after the second surgery. She was treated
with temozolomide-irinotecan chemotherapy, followed by
craniospinal radiotherapy and by a 1-year metronomic
temozolomide-irinotecan maintenance. This child is alive and
in CR with a follow-up of more than a year, without receiving
high-dose chemotherapy. Three other children received chemo-
therapy with etoposide/carboplatin after a surgical resection (2
partial and 1 total) and radiotherapy after thiotepa. One of them
received a maintenance treatment with temozolomide. Those
children are alive with a follow-up of respectively 1, 1.3, and
5.8 years.
Of note, 6 tumors out of the 16 tumors of who received
radiotherapy progressed and 10 children are alive. All patients
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alive and in complete remission underwent complete surgical
resection and received radiotherapy.
The median time of follow-up for the whole population
was 0.9 years (range 0.1 to 15.3 years). The 1-year event-
free survival (EFS) and overall survival (OS) rate were
36 % CI 95 % (23–55) and 45 % CI 95 % (31–64), re-
spectively (Figs. 1 and 2). The median EFS and OS rate
were 5.4 and 10.7 months, respectively. The median time
to first progression/relapsed was 4.3 months (range, 0.9–
44.8 months). Twenty-seven relapses were observed,
74 % were localized, 22 % were localized and metastatic,
and 4 % were only metastatic.
Prognostic factors
The univariate analysis indicates that complete surgical
resection, radiotherapy, and high-dose chemotherapy were
significantly associated with a better OS (respectively,
p < 0.003, p < 0.0001, and p < 0.012). Furthermore,
Table 1 Patient characteristics
Total ETANTR MedulloeP ETMR EP
Number (%) 38 (100 %) 17(45 %) 13(34 %) 8(21 %) 0
Median age (months) (min-max) 31 (2.8–141) 32.9 (15.5–141) 31.1 (2.9–143.4) 27.2 (12.5–43.8)
Mean age (months) (σ) 40.8 [6] 33.4 (9.5) 60.3 (53.5) 27.3 (10.5)
Sex
% Male 26 70.6 84.6 62.5
% Female 72 29.4 15.4 37.5
Sex ratio 0.4 0.4 0.2 0.4
Median time to diagnosis (days) (min-max) 22 (1–203) 32 (1–172) 28 (4–203) 23.5 (15–615)
Clinical signs, %*
Sided weakness 34 53 7.7 37.5
Confusion 26 23.5 30.8 25
Increased IP 53 53 69.2 25
Seizures 21 23.5 15.4 0
Cerebellar syndrome 21 23.5 15.4 25
Torticolis 8 0 15.4 12.5
Visual impairment 11 11.8 15.4 0
Others 3 5.9 7.7 12.5
MV 3 5.9 0 0
Location, %
Supratentorial 66 76.4 53.8 62.5
Infratentorial 26.1 6 46.2 37.5
Other 7.9 17.6 0 0
Metastatic CNS %
Yes 18 23.5 23.1 0
No 79 76.5 69.2 0
MV 2.6 0 7.7 0
σ range,Mmale, F female,MedulloeP medulloepithelioma, EP ependymoblastoma, IP intracranial pressure, CNS central nervous system,MVmissing
values
*Total can be over 100 % as one patient can present several clinical signs
Table 2 Histopathological and biomolecular characteristics
Histopathological review
Number at initial diagnosis (%) 38 (100 %)
Number of changes in diagnosis (%) 6 (16 %)
LIN28
Number of patients analyzed (%) 11 (29 %)
Number of positive staining (%) 11 (100 %)
ampl_19q13.42
Number of patients analyzed (%) 12 (32 %)
Number of positive (%) 10 (83 %)
Gain of chromosome 2
Number of patients analyzed (%) 11 (29 %)
Number of positive (%) 3 (27 %)
Other chromosomics gains
Number of patients analyzed (%) 11 (29 %)
Number of positive (%) 6 (54 %)
302 Childs Nerv Syst (2016) 32:299–305
according to the multivariate analysis, radiotherapy with a
relative risk (RR) of 41.8 CI 95 % (9.4–186) p < 0.0001,
surgical complete resection with a 7.9 CI 95 % (2.6–23.5)
p < 0.0002, and high-dose chemotherapy with a RR 3.5 CI
95 % (1.3–9.5) p = 0.012 were prognostic factors associ-
ated with a better OS.
Discussion
ETMR is a new entity, which encompasses ETAN-TR,
ependymoblastomas, medulloepitheliomas. Indeed, those tu-
mors seem to present clinical, histopathological, and molecu-
lar similarities [2–4]. As those tumors are rare, have been only
Table 3 Treatment strategy and outcome
Number Sex Age (year) Location CNS Meta Surgery Chemotherapy High-dose
chemotherapy
RX Outcome Last news (m)
1 F 1.3 Infra Yes Total VP-Carbo No No Death 1.6
2 F 2.6 Supra No Total VP-carbo X2 No No Death 11.3
3 F 11.5 Supra No Total No No Yes Alive, CR 183.9
4 F 3.6 Supra No Partial TEMIRI X3/maintenance No Yes Alive, CR 13.4
5 F 11.8 Infra No Total VP-carbo X2 Thio Yes Alive CR 12.2
6 M 3.6 Infra No Partial VP-carbo X2 No No Death 4.2
7 F 2.3 Supra No Partial VP-carbo X2 No No Death 4.3
8 M 1.5 Infra No Partial VP-carbo X2 Thio X2/TMZ Yes Alive, PR 15.9
9 F 2.2 Supra No Partial VP-Carbo X2 No No Death 7.3
10 F 2.6 Supra No Partial VP-carbo X2 Mel/Cis No Death 6.3
11 F 2.7 Supra No Total VP-carbo X2 Mel-Cis X2 No Death 7.6
12 M 2.9 Spinal cord Yes Total VP-carbo X2 Mel-Cis X2/Thio Yes Alive, CR 43.2
13 F 2.2 Supra No Total VP-carbo/carbo Mel-Cis X2/Thio Yes Alive, CR 143.6
14 F 3.3 Supra No Total VP-carbo X2 Mel/Cis/Mel/Thio No Death 10.6
15 M 1.6 Supra Yes Partial VP-carbo X2 Mel/Cis No Death 7.8
16 F 1.3 Supra No Partial VP-carbo X2 Mel/Thio No Death 7.8
17 F 3 Supra No Partial VP-carbo X2 Mel/Cis/Thio X2 Yes Death 16.9
18 M 8.1 Infra No Partial VP-carbo X2 Mel/Cis No Death 9.6
19 F 3.2 Supra No Partial VP-carbo X2 Mel/Cis/Thio Yes Alive, PR 90.9
20 F 6.8 Supra No Total VP-carbo X2 Mel-Cis X2 Yes Alive, CR 63.8
21 F 2 Supra No Partial VP-carbo X2 Mel X2/Thio X2 Yes Alive, CR 143.4
22 F 3.5 Supra No Partial VP-carbo X2 Mel/Cis No Death 4.5
23 F 2.5 Supra Yes Partial VP-carbo X2 Mel/Thio X2 No Death 8
24 M 1.3 Supra + Infra Yes Partial VP-carbo X2 Mel/Cis/Mel No Death 10.1
25 M 2.6 Infra No Biopsy VP-carbo X2 Mel No Death 6.5
26 M 1.4 Infra No Total VP-carbo X2 Mel-Cis X2/Thio Yes Death 21.2
27 F 3.2 Supra No Partial VP-carbo X2 Mel/Cis No Death 8.3
28 F 2.6 Infra No Total VP-carbo X2 Mel-Cis X2/Thio Yes Alive CR 103.3
29 F 1.8 Supra No Total VP-carbo X2 Mel-Cis X2/Thio No Death 13
30 F 4.3 Supra No Partial VP-carbo X2 Mel/Cis Yes Death 10
31 F 3.3 Supra No Total VP-carbo X2 Mel/Cis No Death 19.2
32 F 0.2 Supra MV Total BBFSOP No No Death 9.2
33 M 2 Supra + Infra Yes Biopsy VP-carbo X2 Mel/Cis No Death 5.3
34 F 11.6 Infra Yes Total VP-carbo X2 Thio X2/TMZ Yes Alive CR 70.5
35 F 1.8 Supra No Total VP-Carbo X2 Mel-Cis X2/Thio Yes Death 29
36 F 3.3 Supra No Partial MV MV Yes Death 11.9
37 F 1 Infra No Partial VP-Carbo X2 Mel No Death 6
38 M 2.3 Supra No Total VP-Carbo X2 Mel/Cis No Death 13
N number, F female,M male, Supra supratentorial, Infra infratentorial,Meta metastasis,MVmissing values, VP etoposide, carbo carboplatin, TEMIRI
temozolomide-irinotecan, TMZ temozolomide, BBSFOP 2 cycles of Paraplatine + Natulan then Vepeside + Cisplatinum then vincristine + cyclophos-
phamide, Mel Melphalan, Cis cisplatinum, Thio thiotepa, Rx radiotherapy, CR complete remission, PR partial remission, y years, m months
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recently described and diagnosis difficult to establish; there is
only a limited number of publications concerning ETMR [2,
3, 7, 8]. The series we report here represents the second largest
series.
The patients’ characteristics we report here appear similar
to those reported in previous studies [2, 10]. ETMR mainly
occurs in young children [1, 2, 7], with a median of age at
diagnosis of 31 months found in our cohort. The sex ratio in
our series is 0.4. This ratio is in line with the ratio reported by
Picard et al. [10], where a sex ratio of 0.6 were found in the 29
included patients. As previously reported, the most frequent
clinical sign is an increased intracranial pressure, which is
commonly found in cerebral tumor in children [11–13]. Clin-
ical signs at diagnosis are similar for all ETMR histological
variants [2]. Our results (Table 1) are consistent with these
findings. Nevertheless, it should be noted that there is no
ependymoblastoma in our series, probably due to the fact that
the number of patients included in the cohort we report here is
limited. A supratentorial location was found in the majority of
the cases (66 %), as previously published [2]. We also report
one patient with an ETMR localized to the spinal cord. This
had never been reported before. Interestingly, metastasis was
present at diagnosis in 18.9 % of the children as reported by
Korshunov et al. [2]. Metastasis were only evidenced using
MRI but were never found on CSF pathological analysis at
diagnosis. Of note, one case had a CSF positivity after second
surgery.
The diagnosis of ETMR appears to be challenging, as il-
lustrated by the fact that among the histopathological review
we report here, there was a change in diagnosis in 16 % cases
(Table 2). The molecular diagnosis with LIN28A and the re-
search of the gain of the chromosome 2 was performed in 11
patients. The amplification of the locus 19q13.42 was per-
formed in 12 patients. LIN28A staining was positive in
100 % of children, and 83 % of children presented an ampli-
fication of the locus 19q13.42. Those results are in line with
the data available in the literature and confirm that ETMR has
a specific molecular signature. Therefore, immuno-
histochemistry for LIN28A and CGHarray for amplification
of the locus 19q13.42 should be done routinely to secure the
diagnosis.
One of the interests of the series we report here relies on the
fact that the majority of the patients were treated
homogenously according to the PNET-HR protocol [9]. De-
spite a multimodal therapy given in 30 patients, progressions
were observed in all patients with a residual tumor during
induction standard therapy or sequential high-dose therapy,
and 26 of them died. Noteworthy, most of the patients present-
ed either a local or both a local and distant relapse highlighting
the aggressiveness of ETMR.
In the literature, radiotherapy was the only prognostic fac-
tor in univariate analysis [11]. This is confirmed by our find-
ings which show that using both univariate and multivariate
analyses, radiotherapy is associated with a better outcome. To
the best of our knowledge, there is no other data on the prog-
nostic factors available in the medical literature. Noteworthy,
radiotherapy is given at the end of the treatment after chemo-
therapy which might select patient and introduce a bias. In the
present series, we also found that a complete surgery and high-
dose chemotherapy were favorable prognostic factors. Indeed,
out the 11 survivors, all but 2 children received high-dose
chemotherapy. This is consistent with the experience of
Dufour et al. [9] who reported the feasibility and effectiveness
of high-dose chemotherapy (2 cycles of thiotepa) followed by
conventional craniospinal radiotherapy with newly diagnosed
high-risk medulloblastoma or supratentorial PNET. In their
study, the 5-year overall survival was 85 % for the whole
45%
IC95%(31-64)1
1
censored
Fig. 1 Overall survival
36%
IC95%(23-55)
censored
1
30%
IC95%(18-49)
2
1
2
Fig. 2 Event-free survival
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cohort. Unfortunately, the impact of high-dose chemotherapy
on long-term survival is difficult to extrapolate from the liter-
ature on ETMR due to small patient numbers. But, such ag-
gressive chemotherapy, as in other embryonal central nervous
system, could compensate for the avoidance or dose reduction
in prophylactic craniospinal irradiation [14]. Such a strategy
might lead to acceptable outcomes both in terms of toxicity
and survival [15].
Patients with ETMR have a poor prognosis with an EFS
and OS of, respectively, 36 % CI 95 % (23–55) and 45 % CI
95 % (31–64). In comparison, Korshunov et al. found a worst
OS (14 %). This may be due to their treatment strategy which
relies on chemotherapy and high-dose chemotherapy after
surgery [4] but not on radiotherapy. Radiotherapy may there-
fore be recommended in children with ETMR. However, as
radiotherapy potentially impairs neurocognitive function, es-
pecially in young children [16], and as children with ETMR
are for the most of all less than 4 years old, benefits and long-
term toxicities have to be balanced.
Conclusion
ETMR are rare cerebral tumors of the young child. A biologic
diagnosis with LIN28A immuno-histochemistry and the
search for amplification of the locus 19q13.42 should be sys-
tematically done to ensure diagnosis. Prognosis remains dis-
mal, but complete surgical removal seems to be an important
part of the treatment. Radiotherapy may be another crucial
point of the treatment but has to be balanced with
neurocognitive toxicity that can be caused in young children.
Chemotherapy andmaintenance chemotherapymay be useful,
but their respective roles remain to be determined.
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